Total net revenues for the first quarter of fiscal 2013 (Q1 13) were $153.6 million. This is compared to $142.8 million reported in the fourth quarter of 2012 (Q4 12) and compared to $135.1 million reported in the first quarter of 2012 (Q1 12). Q1 13 Invisalign clear aligner revenue was $141.6 million, compared to $132.8 million in Q4 12 and $123.3 million in Q1 12. As expected, Q1 13 clear aligner revenue includes $4.4 million from the planned consolidation of Vivera Retainer product shipments from four shipments per year down to one shipment per year, as well as a $2.7 million decrease in revenue due to the change in our mid-course correction policy effective June 15, 2013. Q1 13 Invisalign clear aligner case shipments were 98.2 thousand, compared to 90.5 thousand in Q4 12 and 85.3 thousand in Q1 12. Q1 13 scanner and CAD/CAM services revenue was $12.0 million, compared to $10.0 million in Q4 12 and compared to $11.8 million in Q1 12. Q1 13 scanner and CAD/CAM services revenue includes $1.4 million that was deferred in Q3 and Q4 2012 for the new iTero scanner upgrade program which was launched in Q1 13.
Net loss for Q1 13 was $42.0 million, or $(0.52) per diluted share. This is compared to net profit of $9.6 million, or $0.12 per diluted share in Q4 12 and net profit of $21.0 million, or $0.26 per diluted share in Q1 12. Net profit for Q1 13 includes an impairment of long-lived assets of $26.3 million and a goodwill impairment charge of $40.7 million. Net profit for Q4 12 includes a goodwill impairment charge of $11.9 million resulting from finalizing our Q3 12 preliminary estimate. Net profit for Q1 12 includes pre-tax acquisition and integration related costs of $0.7 million, pre-tax severance and benefit costs of $0.5 million with a total tax effect of $0.6 million.
Prescott continued, "During the quarter we launched SmartTrack, our next generation aligner material, which is now the standard aligner material for Invisalign clear aligners worldwide. We have received consistently positive initial feedback from our customers and their patients. We're excited about the potential for SmartTrack material to help doctors increase confidence in using Invisalign more often and for more complex cases due to the improved control of tooth movements and the added benefit of increased patient comfort. We are committed to improving the Invisalign customer experience by continually evaluating and striving to improve our products, customer support processes, and policies to help doctors achieve the best results for their patients."
As previously disclosed, beginning in Q1 13, Align began consolidating Vivera Retainer shipments down to one shipment per year instead of four shipments per year. As a result, the full amount of Vivera Retainer revenue is now recognized upon shipment rather than ratably over four quarters. For Q1 13 clear aligner revenue includes $4.4 million from consolidating Vivera Retainer product shipments. This shipment change was based on feedback from our customers that it would make their practices more efficient.
To supplement our consolidated financial statements, we use the following non-GAAP financial measures: non-GAAP gross profit, non-GAAP operating expense, non-GAAP operating margin, non-GAAP net profit, non-GAAP earnings per diluted share, EBITDA and adjusted EBITDA. Detailed reconciliations between GAAP and non-GAAP information are contained in the tables following the financial tables of this release. Starting in fiscal year 2013, amortization of acquired intangible assets is no longer excluded as a non-GAAP measure. This expense is included in GAAP gross profit, operating expenses, profit (loss) from operations and net profit (loss) for the periods presented below and therefore is no longer a reconciling item.
Non-GAAP net profit for Q1 13 was $21.2 million, or $0.26 per diluted share. This is compared to non-GAAP net profit of $21.5 million, or $0.26 per diluted share in Q4 12 and non-GAAP net profit of $21.5 million, or $0.26 per diluted share in Q1 12.
Total stock-based compensation expense included in Q1 13 was $6.4 million compared to $6.0 million in Q4 12 and $4.9 million in Q1 12. Stock based compensation expense included in GAAP gross margin in Q1 13 was $0.6 million, and Q4 12 and Q1 12 was $0.5 million. Stock-based compensation expense included in GAAP operating expense in Q1 13 was $5.8 million compared to $5.5 million in Q4 12 and $4.4 million in Q1 12.
Liquidity and Capital Resources
As of March 31, 2013, Align Technology had $377.4 million in cash, cash equivalents, and marketable securities compared to $356.1 million as of December 31, 2012. During Q1 13, we purchased approximately 75 thousand shares of our common stock at an average price of $32.47 per share for a total of approximately $2.4 million. There remains approximately $92.7 million available under the Company's existing stock repurchase authorization.
Q2 Fiscal 2013 Business Outlook
For the second quarter of fiscal 2013 (Q2 13), Align Technology expects net revenues to be in a range of $153.6 million to $157.4 million. Invisalign clear aligner case shipments for Q2 13 are expected to be in a range of 102.2 to 104.7 thousand cases, which reflect a year-over-year increase of 7.2% to 9.8%. Earnings per diluted share for Q2 13 is expected to be in a range of $0.26 to $0.28.
Align Web Cast and Conference Call
Align Technology will host a conference call today, April 18, 2013 at 4:30 p.m. ET, 1:30 p.m. PT, to review its first quarter 2012 results, discuss future operating trends and business outlook. The conference call will also be web cast live via the Internet. To access the web cast, go to the "Events & Presentations" section under Company Information on Align Technology's Investor Relations web site at http://investor.aligntech.com. To access the conference call, please dial 201-689-8261 approximately fifteen minutes prior to the start of the call. An archived audio web cast will be available beginning approximately one hour after the call's conclusion and will remain available for approximately 12 months. Additionally, a telephonic replay of the call can be accessed by dialing 877-660-6853 with conference number 411500 followed by #. For international callers, please dial 201-612-7415 and use the same conference number referenced above. The telephonic replay will be available through 5:30 p.m. ET on April 26, 2013.
About Align Technology, Inc.
Align Technology designs, manufactures and markets Invisalign, a proprietary method for treating malocclusion, or the misalignment of teeth. Invisalign corrects malocclusion using a series of clear, nearly invisible, removable appliances that gently move teeth to a desired final position. Because it does not rely on the use of metal or ceramic brackets and wires, Invisalign significantly reduces the aesthetic and other limitations associated with braces. Invisalign is appropriate for treating adults and teens. Align Technology was founded in March 1997 and received FDA clearance to market Invisalign in 1998. The Invisalign product family includes Invisalign, Invisalign Teen, Invisalign Assist, Invisalign Express 10, Invisalign Express 5, Invisalign Lite, and Vivera Retainers. To learn more about Invisalign or to find an Invisalign trained doctor in your area, please visit www.invisalign.com.
Cadent Holdings, Inc. is a subsidiary of Align Technology and is a leading provider of 3D digital scanning solutions for orthodontics and dentistry. The Cadent family of products includes the iTero scanning systems, OrthoCAD iCast and OrthoCAD iRecord. For additional information, please visit www.cadentinc.com.
About non-GAAP Financial Measures
To supplement our consolidated financial statements and our business outlook, we use the following non-GAAP financial measures: non-GAAP gross profit, non-GAAP operating expenses, non-GAAP profit from operations, non-GAAP net profit and non-GAAP earnings per share, which exclude, as applicable, acquisition and integration related costs, severance and benefit costs, impairment of goodwill, impairment of long-lived assets and any related income tax-related adjustments, and EBITDA and adjusted EBITDA. The presentation of this financial information is not intended to be considered in isolation, or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.
We use these non-GAAP financial measures for financial and operational decision making and as a means to evaluate period-to-period comparisons. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding our "core operating performance". Management believes that "core operating performance" represents Align's performance in the ordinary, ongoing and customary course of its operations. Accordingly, management excludes from "core operating performance" certain expenditures and other items that may not be indicative of our operating performance including discrete cash and non-cash charges that are infrequent or one-time in nature. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting and analyzing future periods. These non-GAAP financial measures also facilitate management's internal evaluation of period-to-period comparisons. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision making and (2) they are provided to and used by our institutional investors and the analyst community to facilitate comparisons with prior and subsequent reporting periods. A reconciliation of the GAAP and non-GAAP financial measures for the quarter and year and a more detailed explanation of each non-GAAP financial measure and its uses are provided in the footnotes to the table captioned "Reconciliation of GAAP to non-GAAP Key Financial Metrics" and "Business Outlook Summary" included at the end of this release.
Forward-Looking Statement
This news release, including the tables below, contains forward-looking statements, including statements regarding certain business metrics for the second quarter of 2013, including anticipated net revenue, gross margin, operating expense, operating income, earnings per share, case shipments and cash. Forward-looking statements contained in this news release and the tables below relating to expectations about future events or results are based upon information available to Align as of the date hereof. Readers are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. As a result, actual results may differ materially and adversely from those expressed in any forward-looking statement. Factors that might cause such a difference include, but are not limited to, difficulties predicting customer and consumer purchasing behavior, the willingness and ability of our customers to maintain and/or increase utilization in sufficient numbers, the possibility that the development and release of new products does not proceed in accordance with the anticipated timeline, the possibility that the market for the sale of these new products may not develop as expected, the risks relating to Align's ability to sustain or increase profitability or revenue growth in future periods while controlling expenses, growth related risks, including capacity constraints and pressure on our internal systems and personnel, our ability to successfully achieve the anticipated benefits from the scanner and the CAD/CAM services business, continued customer demand for our existing and new products, changes in consumer spending habits as a result of, among other things, prevailing economic conditions, levels of employment, salaries and wages and consumer confidence, the timing of case submissions from our doctors within a quarter, acceptance of our products by consumers and dental professionals, foreign operational, political and other risks relating to Align's international manufacturing operations, Align's ability to protect its intellectual property rights, continued compliance with regulatory requirements, competition from existing and new competitors, Align's ability to develop and successfully introduce new products and product enhancements, the loss of key personnel and impairments in the book value of goodwill or other intangible assets. These and other risks are detailed from time to time in Align's periodic reports filed with the Securities and Exchange Commission, including, but not limited to, its Annual Report on Form 10-K for the fiscal year ended December 31, 2012, which was filed with the Securities and Exchange Commission on March 1, 2013. Align undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
| ALIGN TECHNOLOGY, INC. | |
| UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |
| (in thousands, except per share data) | |
| | | | | | | |
| | | Three Months Ended | |
| | | March 31, 2013 | | | March 31, 2012 | |
| | | | | | | |
| Net revenues | | $ | 153,580 | | | | 135,079 | |
| | | | | | | | | |
| Cost of revenues | | | 40,731 | | | | 34,319 | |
| | | | | | | | | |
| Gross profit | | | 112,849 | | | | 100,760 | |
| | | | | | | | | |
| Operating expenses: | | | | | | | | |
| Sales and marketing | | | 42,281 | | | | 38,717 | |
| General and administrative | | | 30,348 | | | | 23,511 | |
| Research and development | | | 11,282 | | | | 10,526 | |
| Impairment of goodwill | | | 40,693 | | | | - | |
| Impairment of long-lived assets | | | 26,320 | | | | - | |
| Total operating expenses | | | 150,924 | | | | 72,754 | |
| | | | | | | | | |
| Profit (loss) from operations | | | (38,075 | ) | | | 28,006 | |
| | | | | | | | | |
| Interest and other income (expense), net | | | (988 | ) | | | (812 | ) |
| | | | | | | | | |
| Profit before income taxes | | | (39,063 | ) | | | 27,194 | |
| | | | | | | | | |
| Provision for income taxes | | | 2,920 | | | | 6,210 | |
| | | | | | | | | |
| Net profit (loss) | | $ | (41,983 | ) | | $ | 20,984 | |
| | | | | | | | | |
| Net profit (loss) per share | | | | | | | | |
| basic | | $ | (0.52 | ) | | $ | 0.26 | |
| diluted | | $ | (0.52 | ) | | $ | 0.26 | |
| | | | | | | | | |
| Shares used in computing net profit (loss) per share | | | | | | | | |
| basic | | | 81,248 | | | | 79,235 | |
| diluted | | | 81,248 | | | | 81,856 | |
| ALIGN TECHNOLOGY, INC. | |
| UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS | |
| (in thousands) | |
| | | | | | | |
| | | March 31, 2013 | | | December 31, 2012 | |
| | | | | | | |
| ASSETS | | | | | | |
| | | | | | | |
| Current assets: | | | | | | |
| Cash and cash equivalents | | $ | 328,745 | | | $ | 306,386 | |
| Restricted cash | | | 508 | | | | 1,575 | |
| Marketable securities, short-term | | | 37,975 | | | | 28,485 | |
| Accounts receivable, net | | | 108,672 | | | | 98,992 | |
| Inventories | | | 15,442 | | | | 15,122 | |
| Other current assets | | | 35,989 | | | | 35,233 | |
| Total current assets | | | 527,331 | | | | 485,793 | |
| | | | | | | | | |
| Marketable securities, long-term | | | 10,680 | | | | 21,252 | |
| Property and equipment, net | | | 72,672 | | | | 79,191 | |
| Goodwill and intangible assets, net | | | 83,971 | | | | 145,013 | |
| Deferred tax assets | | | 28,417 | | | | 21,609 | |
| Other long-term assets | | | 3,174 | | | | 3,454 | |
| | | | | | | | | |
| Total assets | | $ | 726,245 | | | $ | 756,312 | |
| | | | | | | | | |
| LIABILITIES AND STOCKHOLDERS' EQUITY | | | | | | | | |
| | | | | | | | | |
| Current liabilities: | | | | | | | | |
| Accounts payable | | $ | 19,748 | | | $ | 19,549 | |
| Accrued liabilities | | | 64,635 | | | | 74,247 | |
| Deferred revenue | | | 59,472 | | | | 61,975 | |
| Total current liabilities | | | 143,855 | | | | 155,771 | |
| | | | | | | | | |
| Other long term liabilities | | | 21,272 | | | | 19,224 | |
| | | | | | | | | |
| Total liabilities | | | 165,127 | | | | 174,995 | |
| | | | | | | | | |
| Total stockholders' equity | | | 561,118 | | | | 581,317 | |
| | | | | | | | | |
| Total liabilities and stockholders' equity | | $ | 726,245 | | | $ | 756,312 | |
| | | | | | | | | |
Starting in fiscal year 2013, amortization of acquired intangible assets is no longer excluded as a non-GAAP measure. This expense is included in GAAP gross profit, operating expenses, profit (loss) from operations and net profit (loss) for the periods presented below and therefore is no longer a reconciling item.
| ALIGN TECHNOLOGY, INC. | |
| RECONCILIATION OF GAAP TO NON-GAAP KEY FINANCIAL METRICS | |
| | | | | | | |
| Reconciliation of GAAP to Non-GAAP Gross Profit | | | | | | |
| (in thousands) | | | | | | |
| | Three Months Ended | |
| | March 31, 2013 | | December 31, 2012 | | March 31, 2012 | |
| | | | | | | | | | |
| GAAP Gross profit | | $ | 112,849 | | | $ | 106,478 | | | $ | 100,760 | |
| Acquisition and integration costs related to cost of revenues (1) | | | - | | | | - | | | | 134 | |
| Severance and benefit costs related to cost of revenues (2) | | | - | | | | - | | | | 300 | |
| Non-GAAP Gross profit | | $ | 112,849 | | | $ | 106,478 | | | $ | 101,194 | |
| | | | | | | | | | | | | |
| Reconciliation of GAAP to Non-GAAP Gross Profit Scanner and CAD/CAM Services | | | | | | | | | | | | |
| (in thousands) | | | | | | | | | | | | |
| | Three Months Ended | |
| | March 31, 2013 | | December 31, 2012 | | March 31, 2012 | |
| | | | | | | | | | | | | |
| GAAP Scanner and CAD/CAM Services gross profit | | $ | 3,522 | | | $ | 1,848 | | | $ | 3,371 | |
| Acquisition and integration costs related to cost of revenues (1) | | | - | | | | - | | | | 134 | |
| Severance and benefit costs related to cost of revenues (2) | | | - | | | | - | | | | 300 | |
| Non-GAAP Gross profit | | $ | 3,522 | | | $ | 1,848 | | | $ | 3,805 | |
| | | | | | | | | | | | | |
| Reconciliation of GAAP to Non-GAAP Operating Expenses | | | | | | | | | | | | |
| (in thousands) | | | | | | | | | | | | |
| | Three Months Ended | |
| | March 31, 2013 | | December 31, 2012 | | March 31, 2012 | |
| | | | | | | | | | | | | |
| GAAP Operating expenses | | $ | 150,924 | | | $ | 89,407 | | | $ | 72,754 | |
| Acquisition and integration costs related to operating expenses (1) | | | - | | | | - | | | | (570 | ) |
| Severance and benefit costs related to operating expenses (2) | | | - | | | | - | | | | (152 | ) |
| Impairment of goodwill (3) | | | (40,693 | ) | | | (11,926 | ) | | | - | |
| Impairment of long-lived assets (4) | | | (26,320 | ) | | | - | | | | - | |
| Non-GAAP Operating expenses | | $ | 83,911 | | | $ | 77,481 | | | $ | 72,032 | |
| | | | | | | | | | | | | |
| Reconciliation of GAAP to Non-GAAP Profit from Operations | | | | | | | | | | | | |
| (in thousands) | | | | | | | | | | | | |
| | Three Months Ended | |
| | March 31, 2013 | | December 31, 2012 | | March 31, 2012 | |
| | | | | | | | | | | | | |
| GAAP Profit (loss) from operations | | $ | (38,075 | ) | | $ | 17,071 | | | $ | 28,006 | |
| Acquisition and integration costs (1) | | | - | | | | - | | | | 704 | |
| Severance and benefit costs (2) | | | - | | | | - | | | | 452 | |
| Impairment of goodwill (3) | | | 40,693 | | | | 11,926 | | | | - | |
| Impairment of long-lived assets (4) | | | 26,320 | | | | - | | | | - | |
| Non-GAAP Profit from operations | | $ | 28,938 | | | $ | 28,997 | | | $ | 29,162 | |
| | | | | | | | | | | | | |
| Reconciliation of GAAP to Non-GAAP Net Profit | | | | | | | | | | | | |
| (in thousands, except per share amounts) | | | | | | | | | | | | |
| | Three Months Ended | |
| | March 31, 2013 | | December 31, 2012 | | March 31, 2012 | |
| | | | | | | | | | | | | |
| GAAP Net profit (loss) | | $ | (41,983 | ) | | $ | 9,559 | | | $ | 20,984 | |
| Acquisition and integration costs (1) | | | - | | | | - | | | | 704 | |
| Severance and benefit costs (2) | | | - | | | | - | | | | 452 | |
| Impairment of goodwill (3) | | | 40,693 | | | | 11,926 | | | | - | |
| Impairment of long-lived assets (4) | | | 26,320 | | | | | | | | | |
| Income tax-related adjustments (5) | | | (3,788 | ) | | | 42 | | | | (594 | ) |
| Non-GAAP Net profit | | $ | 21,242 | | | $ | 21,527 | | | $ | 21,546 | |
| | | | | | | | | | | | | |
| Diluted Net profit (loss) per share: | | | | | | | | | | | | |
| GAAP | | $ | (0.52 | ) | | $ | 0.12 | | | $ | 0.26 | |
| Non-GAAP | | $ | 0.26 | | | $ | 0.26 | | | $ | 0.26 | |
| | | | | | | | | | | | | |
| Shares used in computing diluted GAAP Net profit (loss) per share | | | 81,248 | | | | 82,981 | | | | 81,856 | |
| Shares used in computing diluted Non-GAAP Net profit per share | | | 83,003 | | | | 82,981 | | | | 81,856 | |
| | | | | | | | | | | | | |
| Reconciliation of GAAP Net Profit to EBITDA and Adjusted EBITDA | | | | | | | | | | | | |
| (in thousands) | | | | | | | | | | | | |
| | Three Months Ended | |
| | March 31, 2013 | | December 31, 2012 | | March 31, 2012 | |
| | | | | | | | | | | | | |
| GAAP Net profit (loss) | | $ | (41,983 | ) | | $ | 9,559 | | | $ | 20,984 | |
| Provision for income taxes | | | 2,920 | | | | 6,840 | | | | 6,210 | |
| Depreciation and amortization | | | 4,944 | | | | 5,278 | | | | 3,899 | |
| EBITDA (6) | | | (34,119 | ) | | | 21,677 | | | | 31,093 | |
| | | | | | | | | | | | | |
| Adjustments or charges: | | | | | | | | | | | | |
| Acquisition and integration related costs (1) | | | - | | | | - | | | | 704 | |
| Severance and benefit costs (2) | | | - | | | | - | | | | 452 | |
| Impairment of goodwill (3) | | | 40,693 | | | | 11,926 | | | | - | |
| Impairment of long-lived assets (4) | | | 26,320 | | | | - | | | | - | |
| EBITDA after adjustments (6) | | $ | 32,894 | | | $ | 33,603 | | | $ | 32,249 | |
| | | | | | | | | | | | | |
(1) Acquisition costs and integration related. We have incurred acquisition-related and other expenses which include legal, banker, accounting and other advisory fees of third parties, retention bonuses, integration and professional fees. We do not engage in acquisitions in the ordinary course of business. We believe that it is important to understand these charges; however, we do not believe that these charges are indicative of future operating results. We believe that eliminating these expenses from our non-GAAP measures is useful because we generally would not have otherwise incurred such expenses in the periods presented as part of our continuing operations.
(2) Severance and benefits costs. These costs are related to the closure of our New Jersey operations and were realized through the first three quarters of 2012. We have engaged in various restructuring and exit activities in 2011 and 2009 that have resulted in costs associated with severance and benefits. Such activity has been a discrete event based on a unique set of business objectives or circumstances, and each has differed from the others in terms of its operational implementation, business impact and scope. We do not engage in restructuring and/or exit activities in the ordinary course of business. We believe that it is important to understand significant severance and benefits costs from restructuring and exit activities and believe that investors benefit from excluding these charges from our operating results to facilitate a more meaningful evaluation of current operating performance and comparisons to past operating performance.
(3) Impairment of goodwill. These costs represent non-cash write-downs of our goodwill generally related to negative trends in market and economic conditions, termination of relationships with distributors, or the increase in completive environment related to our Scanner and CAD/CAM Services reporting unit. We remove the impact of these charges to our operating performance to assist in assessing our ability to generate cash from operations. We believe this may be useful information to users of our financial statements and therefore we have excluded these charges for purposes of calculating these non-GAAP measures to facilitate an evaluation of our current operating performance, particularly in terms of liquidity.
(4) Impairment of long-lived assets. These costs represent non-cash write-downs of our long-lived assets generally related to the increase in completive environment related to our Scanner and CAD/CAM Services reporting unit. As a result of these conditions, we have assessed that our asset group within the reporting unit was not recoverable and therefore recorded an impairment charge. We remove the impact of these charges to our operating performance to assist in assessing our ability to generate cash from operations. We believe this may be useful information to users of our financial statements and therefore we have excluded these charges for purposes of calculating these non-GAAP measures to facilitate an evaluation of our current operating performance, particularly in terms of liquidity.
(5) Income tax-related adjustments. Non-GAAP financial information for the quarter is adjusted for a tax rate equal to our annual estimated tax rate on non-GAAP income. This rate is based on our estimated annual GAAP income tax rate forecast, adjusted to account for discrete tax items and items excluded from GAAP income in calculating the non-GAAP financial measures presented above. Our estimated tax rate on non-GAAP income is determined annually and may be re-calculated during the year to take into account events or trends that we believe materially impact the estimated annual rate.
(6) EBITDA and adjusted EBITDA. We use EBITDA as a performance measure for benchmarking against our peers and competitors. We believe EBITDA is useful to investors because it is frequently used by securities analysts, investors and other interested parties to evaluate companies in the medical technology industry. We also use adjusted EBITDA which excludes certain special or non-recurring expenses, net of certain special or non-recurring benefits, detailed in the reconciliation tables that accompany this release, as an internal measure of business operating performance. We believe such financial measures provide a meaningful perspective of the underlying operating performance to our current business. EBITDA and adjusted EBITDA are not recognized terms under GAAP. Because all companies do not calculate EBITDA and similarly titled financial measures in the same way, those measures as used by other companies may not be consistent with the way we calculate such measures and should not be considered as alternative measures of operating or net profit.
| ALIGN TECHNOLOGY | |
| Q1 2013 EARNINGS RELEASE ADDITIONAL DATA | |
| REVENUE PERFORMANCE AND CLEAR ALIGNER METRICS | |
| (in thousands except per share data) | |
| | |
| | | | Q1 | | | | Q2 | | | | Q3 | | | | Q4 | | | FISCAL | | | | Q1 | |
| | | | 2012 | | | | 2012 | | | | 2012 | | | | 2012 | | | | 2012 | | | | 2013 | |
| Invisalign Clear Aligner Revenues by Geography: | | | | | | | | | | | | | | | | | | | | | | | | |
| North America | | $ | 86,871 | | | $ | 92,997 | | | $ | 89,568 | | | $ | 91,686 | | | $ | 361,122 | | | $ | 97,045 | |
| North American Orthodontists | | | 41,688 | | | | 43,942 | | | | 43,090 | | | | 43,812 | | | | 172,532 | | | | 48,859 | |
| North American GP Dentists | | | 45,183 | | | | 49,055 | | | | 46,478 | | | | 47,874 | | | | 188,590 | | | | 48,186 | |
| International | | | 29,700 | | | | 32,883 | | | | 29,700 | | | | 32,513 | | | | 124,796 | | | | 31,818 | |
| Non-case* | | | 6,757 | | | | 7,789 | | | | 7,457 | | | | 8,660 | | | | 30,663 | | | | 12,709 | |
| Total Clear Aligner Revenue | | $ | 123,328 | | | $ | 133,669 | | | $ | 126,725 | | | $ | 132,859 | | | $ | 516,581 | | | $ | 141,572 | |
| *includes Invisalign training, ancillary products, and retainers | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Invisalign Clear Aligner Revenues by Product: | | | | | | | | | | | | | | | | | | | | | | | | |
| Invisalign Full | | $ | 82,424 | | | $ | 88,617 | | | $ | 80,294 | | | $ | 87,265 | | | $ | 338,600 | | | $ | 85,914 | |
| Invisalign Express/Lite | | | 11,806 | | | | 13,632 | | | | 12,779 | | | | 13,269 | | | | 51,486 | | | | 16,083 | |
| Invisalign Teen | | | 15,148 | | | | 16,380 | | | | 19,144 | | | | 16,455 | | | | 67,127 | | | | 18,573 | |
| Invisalign Assist | | | 7,193 | | | | 7,251 | | | | 7,051 | | | | 7,210 | | | | 28,705 | | | | 8,293 | |
| Non-case* | | | 6,757 | | | | 7,789 | | | | 7,457 | | | | 8,660 | | | | 30,663 | | | | 12,709 | |
| Total Clear Aligner Revenue | | $ | 123,328 | | | $ | 133,669 | | | $ | 126,725 | | | $ | 132,859 | | | $ | 516,581 | | | $ | 141,572 | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Average Invisalign Selling Price (ASP), as billed: | | | | | | | | | | | | | | | | | | | | | | | | |
| Total Worldwide Blended ASP | | $ | 1,370 | | | $ | 1,335 | | | $ | 1,320 | | | $ | 1,375 | | | $ | 1,350 | | | $ | 1,305 | |
| International ASP | | $ | 1,485 | | | $ | 1,455 | | | $ | 1,355 | | | $ | 1,455 | | | $ | 1,440 | | | $ | 1,360 | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Invisalign Clear Aligner Cases Shipped by Geography: | | | | | | | | | | | | | | | | | | | | | | | | |
| North America | | | 65,280 | | | | 72,685 | | | | 70,610 | | | | 68,140 | | | | 276,715 | | | | 74,730 | |
| North American Orthodontists | | | 32,235 | | | | 35,420 | | | | 35,885 | | | | 33,505 | | | | 137,045 | | | | 38,000 | |
| North American GP Dentists | | | 33,045 | | | | 37,265 | | | | 34,725 | | | | 34,635 | | | | 139,670 | | | | 36,730 | |
| International | | | 19,985 | | | | 22,595 | | | | 21,905 | | | | 22,340 | | | | 86,825 | | | | 23,445 | |
| Total Cases Shipped | | | 85,265 | | | | 95,280 | | | | 92,515 | | | | 90,480 | | | | 363,540 | | | | 98,175 | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Invisalign Clear Aligner Cases Shipped by Product: | | | | | | | | | | | | | | | | | | | | | | | | |
| Invisalign Full | | | 57,145 | | | | 62,510 | | | | 57,400 | | | | 57,920 | | | | 234,975 | | | | 61,245 | |
| Invisalign Express/Lite | | | 12,855 | | | | 15,300 | | | | 14,610 | | | | 15,940 | | | | 58,705 | | | | 18,940 | |
| Invisalign Teen | | | 9,935 | | | | 11,860 | | | | 15,265 | | | | 11,255 | | | | 48,315 | | | | 12,580 | |
| Invisalign Assist | | | 5,330 | | | | 5,610 | | | | 5,240 | | | | 5,365 | | | | 21,545 | | | | 5,410 | |
| Total Cases Shipped | | | 85,265 | | | | 95,280 | | | | 92,515 | | | | 90,480 | | | | 363,540 | | | | 98,175 | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Number of Invisalign Doctors Cases Shipped to: | | | | | | | | | | | | | | | | | | | | | | | | |
| North American Orthodontists | | | 4,460 | | | | 4,575 | | | | 4,660 | | | | 4,615 | | | | 5,665 | | | | 4,760 | |
| North American GP Dentists | | | 11,365 | | | | 12,120 | | | | 11,925 | | | | 11,685 | | | | 19,285 | | | | 12,520 | |
| International | | | 5,085 | | | | 5,480 | | | | 5,400 | | | | 5,715 | | | | 9,285 | | | | 5,840 | |
| Total Doctors Cases were Shipped to Worldwide | | | 20,910 | | | | 22,175 | | | | 21,985 | | | | 22,015 | | | | 34,235 | | | | 23,120 | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Invisalign Doctor Utilization Rates*: | | | | | | | | | | | | | | | | | | | | | | | | |
| North American Orthodontists | | | 7.2 | | | | 7.7 | | | | 7.7 | | | | 7.3 | | | | 24.2 | | | | 8.0 | |
| North American GP Dentists | | | 2.9 | | | | 3.1 | | | | 2.9 | | | | 3.0 | | | | 7.2 | | | | 2.9 | |
| International | | | 3.9 | | | | 4.1 | | | | 4.1 | | | | 3.9 | | | | 9.4 | | | | 4.0 | |
| Total Utilization Rates | | | 4.1 | | | | 4.3 | | | | 4.2 | | | | 4.1 | | | | 10.6 | | | | 4.3 | |
| * # of cases shipped/# of doctors to whom cases were shipped | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Number of Invisalign Doctors Trained: | | | | | | | | | | | | | | | | | | | | | | | | |
| North American Orthodontists | | | 90 | | | | 95 | | | | 125 | | | | 75 | | | | 385 | | | | 65 | |
| North American GP Dentists | | | 720 | | | | 995 | | | | 675 | | | | 920 | | | | 3,310 | | | | 690 | |
| International | | | 715 | | | | 965 | | | | 685 | | | | 780 | | | | 3,145 | | | | 905 | |
| Total Doctors Trained Worldwide | | | 1,525 | | | | 2,055 | | | | 1,485 | | | | 1,775 | | | | 6,840 | | | | 1,660 | |
| Total to Date Worldwide | | | 71,180 | | | | 73,235 | | | | 74,720 | | | | 76,495 | | | | 76,495 | | | | 78,155 | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Scanner and CAD/CAM Services Revenue: | | | | | | | | | | | | | | | | | | | | | | | | |
| North America Scanner and CAD/CAM Services | | $ | 11,120 | | | $ | 11,752 | | | $ | 9,439 | | | $ | 9,940 | | | $ | 42,251 | | | $ | 11,952 | |
| International Scanner and CAD/CAM Services | | | 631 | | | | 205 | | | | 332 | | | | 41 | | | | 1,209 | | | | 56 | |
| Total Scanner and CAD/CAM Revenue | | $ | 11,751 | | | $ | 11,957 | | | $ | 9,771 | | | $ | 9,981 | | | $ | 43,460 | | | $ | 12,008 | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Scanner Revenue | | $ | 5,361 | | | $ | 6,032 | | | $ | 4,023 | | | $ | 4,643 | | | $ | 20,059 | | | $ | 6,625 | |
| CAD/CAM Services Revenue | | | 6,390 | | | | 5,925 | | | | 5,748 | | | | 5,338 | | | | 23,401 | | | | 5,383 | |
| Total Scanner and CAD/CAM Services Revenue | | $ | 11,751 | | | $ | 11,957 | | | $ | 9,771 | | | $ | 9,981 | | | $ | 43,460 | | | $ | 12,008 | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Total Revenue by Geography: | | | | | | | | | | | | | | | | | | | | | | | | |
| Total North America Revenue | | $ | 97,991 | | | $ | 104,749 | | | $ | 99,007 | | | $ | 101,626 | | | $ | 403,373 | | | $ | 108,997 | |
| Total International Revenue | | | 30,331 | | | | 33,088 | | | | 30,032 | | | | 32,554 | | | | 126,005 | | | | 31,874 | |
| Total Non-case Revenue | | | 6,757 | | | | 7,789 | | | | 7,457 | | | | 8,660 | | | | 30,663 | | | | 12,709 | |
| Total Worldwide Revenue | | $ | 135,079 | | | $ | 145,626 | | | $ | 136,496 | | | $ | 142,840 | | | $ | 560,041 | | | $ | 153,580 | |
| | |
| Note: Historical public data may differ due to rounding. Additionally, rounding may effect totals. | |
| | |
| ALIGN TECHNOLOGY, INC. | |
| BUSINESS OUTLOOK SUMMARY | |
| (unaudited) | |
| | | |
| The outlook figures provided below and elsewhere in this press release are approximate in nature since Align's business outlook is difficult to predict. Align's future performance involves numerous risks and uncertainties and the company's results could differ materially from the outlook provided. Some of the factors that could affect Align's future financial performance and business outlook are set forth under "Forward Looking Information" above in this press release. | |
| | | |
| Financials | | |
| (in millions, except per share amounts and percentages) | |
| | | |
| | Q2 2013 | |
| | | | |
| Net Revenue | $ | 153.6 - $157.4 | |
| | | | |
| Gross Profit | $ | 114.5 - $118.0 | |
| | | | |
| Gross Margin | | 74.5% - 75.0 | % |
| | | | |
| Operating Expenses | $ | 85.7 - $87.1 | |
| | | | |
| Operating Margin | | 18.7% - 19.7 | % |
| | | | |
| Net Income per Diluted Share | $ | 0.26 - $0.28 | |
| | | | |
| Stock Based Compensation Expense: | | | |
| Cost of Revenues | $ | 0.7 | |
| Operating Expenses | $ | 6.6 | |
| Total Stock Based Compensation Expense | $ | 7.3 | |
| | | | |
| Business Metrics: | | | |
| | | Q2 2013 | |
| Case Shipments | | 102.2K - 104.7K | |
| Cash, Cash Equivalents, and Marketable Securities | $ | 405M - $415M * | |
| Capex | $ | 4.5M - $6.0M | |
| Depreciation & Amortization | $ | 4.0M - $4.5M | |
| Diluted Shares Outstanding | | 83.9M | |
| | | | |
| * Excludes any stock repurchases during the quarter | | | |
Investor Relations Contact
Shirley Stacy
Align Technology, Inc.
(408) 470-1150
sstacy@aligntech.com
Press Contact
Shannon Mangum Henderson
Ethos Communication, Inc.
(678) 261-7803
align@ethoscommunication.com
